Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune
NEW YORK, NY, July 22, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired...
Publisher
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Royalty Pharma
- Region
- Global
- Scope
- Industry
- Published
- July 22, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
NEW YORK, NY, July 22, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired...
Source route
Continue on royaltypharma.com
Leave the platform to read the original full article on the publisher site.
Source: Royalty Pharma
Scope: Industry
Related coverage